Estriol

Also known as: Oestriol

Drug #1786

Estriol is a naturally occuring oestrogen with actions and uses similar to those of oestradiol. Estriol is claimed to have a mild proliferative effect on endometrium. Estriol is used for menopausal hormone replacement therapy (HRT). Estriol is used intravaginally for the short-term treatment of menopausal atrophic vaginitis as acream or as pessaries.

← Previous drug Next drug →

Primary Characteristics

Estriol is also known as Oestriol.

It is of Semi Synthetic origin and belongs to Oestrone Sulphate.

Molecular Weight: 288.4 · pK_a: 13.62 · Solubility in Water: Insoluble · Solubility in Alcohol: Sparingly Soluble · Non-proprietary name: Estriol.

Pharmacokinetics

Elimination: plasma half-life is 64 ± 11 min.

Indications

Estriol is also indicated for secondary conditions like Infertility, Vaginitis.

Contraindications

Estriol is contraindicated in conditions like Pregnancy, Breast feeding.

Dosage

Estriol's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
1.75 mg	1.75 mg	Every 24h	PO	For upto 1 month. Then 0.5-1.0 mg daily until restoration of epithelial integrity.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

The signs and symptoms that are produced after acute overdosage of Estriol are Nausea, Abdominal cramps, Pain, Tendernen, Break through bleeding.

Estriol is known to cause more or less tolerable side effects which are usually transient. These include Abdominal cramps, Breast enlargement, Sodium and fluid retention, Vomiting , Weight changes.

Warnings / Precautions

Prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer; migraine (or migraine like headaches); interrupt treatment periodicaally to assess need for continued treatment; diabetes (increased risk of heart disease); history of breast nodulesor fibrocystic disease; closely monitor breast status; risk factors for oestrogen-dependent tumours (e.g breast-cancer in first degree relative); uterine fibroids may increase in size, symptoms of endometriosis may be exacerbated; factors predisposing to thromboembolism; presence of phospholipid antibodies (increased risk of thrombotic events).

Available Brands

None recorded.

Drug Classification

1.18.4 — Estrogens, their combinations and related preparations